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Abstract 
The Value of 18F-FDG PET/contrast-enhanced CT in Detection of Tumor Thrombus 
Purpose 
The differentiation between tumor and bland thromboses is important as the management 
differs. Retrospectively, we aim to evaluate the utility of FDG PET in detecting and 
differentiating tumor from bland thromboses; and if FDG PET provides additional value to 
contrast-enhanced CT for tumor thrombus detection.  
Materials and Methods 
Twenty-four sites of venous thromboembolism, detected on PET/CT, were retrospectively 
reviewed. Classification of type of thrombosis was based on histology and radiological 
follow-up. We evaluated the presence of contrast-enhanced CT findings that were 
suggestive of tumor thrombosis; sign of invasion, neovascularity and enhancement. 
Metabolic activity by means of SUVmax was measured by drawing ROI at the site of 
thrombosis. Mann-Whitney U test was used to compare the mean SUVmax between 
thromboses and internal references. We used ROC analysis to identify the optimal cut-off 
value of SUVmax for detection of tumor thrombosis.  
Results 
Twenty-four sites of venous thromboembolism were identified in 15 patients. All tumor 
thromboses demonstrated at least one positive sign on contrast-enhanced CT; whereas 33% 
of bland thromboses had the same finding. The difference between tumor and bland 
thrombus SUVmax was statistically significant (p<0.005). On ROC analysis, a cut-off of 
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SUVmax 2.25 (sensitivity 78%, specificity 100%) was suggested to differentiate tumor from 
bland thrombosis.   
Conclusion 
PET/CT is able to differentiate tumor from bland thrombosis, with an optimal cut-off value 
of SUVmax 2.25. The metabolic information increases the diagnostic accuracy of tumor 
thrombus, and is a useful adjunct to the described features on contrast-enhanced CT.  
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Introduction 
Patients with underlying malignancy are predisposed to venous thromboembolism (VTE) 
secondary to the direct and indirect influences of malignancy on every element of Virchow’s 
triad. With increasing use of imaging as part of disease assessment, there is increasing trend 
of incidental VTE detection. VTE can be divided into two broad categories- bland thrombus 
and tumor thrombus.   
Tumor thrombus tends to be associated with solid tumor, including renal cell carcinoma1, 2, 
Wilm’s tumor3, testicular tumor4, adrenal cortical carcinoma, lymphoma5, 6, pancreatic 
cancer7, osteosarcoma8, Ewing’s sarcoma9 and hepatocellular carcinoma10, 11. 
Tumor thrombosis is an uncommon clinical entity for which the true incidence is unknown. 
It is estimated that 4-10% of renal cell carcinoma are associated with venous tumor 
thrombosis in the renal vein or inferior vena cava 12 and a higher incidence of 20-30% are 
found in hepatocellular carcinoma10, 11. The prognostic value of the presence of tumor 
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thrombosis varies according to different tumor types; for example, portal vein tumor 
thrombosis in hepatocellular carcinoma is a poor prognostic factor, as surgical resection and 
trans-catheter arterial chemoembolization lack the desired therapeutic results10, 11; while no 
impact on survival has been demonstrated in nephroblastoma with intracaval or atrial 
tumor thrombus 13. However, consensus agrees that the primary treatment for tumor 
thrombosis should be surgical thrombectomy if possible, or chemo-radiation; while there is 
no role of anticoagulation therapy. Therefore, it remains important to be able to identify 
and differentiate tumor thrombosis from bland thrombosis to avoid the unnecessary use of 
anticoagulation, which carries the inherent risk of bleeding complications.  
There are several contrast-enhanced CT features, previously described, which are suggestive 
of tumor thrombosis14, 15. These include direct or contiguous invasion from tumor or 
metastasis (sensitivity of 32% and 62% respectively), neovascularity (sensitivity 43%, 
specificity 100%) and generalized intra-thrombus enhancement (sensitivity 83%) 14. 
Dramatic venous expansion of portal vein in hepatocellular carcinoma has also been 
described 14 and the cut-off mean diameter ≧23 mm would give rise to 86% sensitivity and 
100% specificity in CT detection of tumor thrombosis.  
Though there are a handful of case reports 16-25, there are only three small retrospective 
series 26-28 that investigated the usefulness of 18 fluoro-deoxyglucose positron emission 
tomography (FDG PET) in detection of tumor thrombus; all concluded that FDG PET can 
differentiate tumor thrombosis from bland VTE based on SUV. Sharma et al 28 suggested a 
cut-off value of maximum standardised uptake value (SUVmax) 3.63 with sensitivity yield of 
72% and specificity of 90%. None of these series have compared the accuracy of the two 
modalities, 18F-FDG PET and contrast-enhanced CT, in differentiating tumor from bland 
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thrombus. We aim to investigate the utility of FDG PET in detecting and differentiating 
tumor from bland thrombus by means of SUVmax; and evaluate if FDG PET provides 
additional information to contrast-enhanced CT for tumor thrombus detection in a cohort of 
patients who underwent FDG PET/contrast-enhanced CT (PET/CT).  
 
Materials and Methods 
The local institutional research and ethics review board approved this retrospective study. 
Patients 
Patients with VTE detected by PET/CT were identified through our database from March 
2007 to May 2011. Demographic data, types of malignancy, clinical outcomes and follow-up 
imaging studies were recorded. 
PET/CT acquisition and interpretation 
Patient was required to fast 6 hour prior to PET/CT examination with glucose level below 
144mg/dl at the time of 18F-FDG injection. 18F-FDG dosage was weight-based: weight (kg) x 
0.13 mCi. PET/CT was acquired using dedicated PET/CT scanner (Discovery VCT; 64 MSCT, 
GE Healthcare Bio-Sciences Corp., Piscataway, NJ) 60 min following 18F-FDG injection. 
Contrast-enhanced CT protocol was as follows: 120 kVp; 200-400mA; field of view, 50cm; 
pitch 0.984:1; intravenous contrast medium (1.5ml/kg) with injection rate of 2.0ml/sec; 
performed 70 sec following intravenous contrast injection in the porto-venous phase. 
Attenuation correction for PET data using CT images was performed and images were 
reconstructed using an ordered-subset expectation maximization iterative algorithm (14 
subsets and two iterations). All PET/CT studies were retrospectively reviewed by an 
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experienced radiologist, trained to report PET/CT and blinded to the clinical or radiological 
follow-up data.  
Sites of thromboses were identified on contrast-enhanced CT; CT features that were 
suggestive tumor thrombosis, i.e. direct or contiguous invasion from tumor, neovascularity 
within the thrombus and generalized intra-thrombus enhancement based on visual analysis 
were documented in both studied groups. Neovascularity and intra-thrombus enhancement 
were assessed qualitatively based on visual analysis as no non-contrast CT was performed as 
part of the PET/CT examination protocol. As venous expansion was only studied in the 
portal vein previously14, while there were various VTE sites involvement in our cohort and 
not exclusively confining to the portal veins, therefore venous expansion was excluded from 
statistical analysis.  
Area of focal hypermetabolic activity corresponding to site of thrombus was measured using 
region of interest (ROI) by means of SUVmax; if no focal 18F-FDG uptake was identified, the 
ROI was manually placed over the site of thrombosis for SUVmax measurement (Figure 1). 
These were categorized into tumor thrombosis uptake (tSUVmax) and bland thrombosis 
uptake (bSUVmax) according the criteria set below based on histology or follow up imaging. 
Mediastinal blood pool uptake (mSUVmax) and background liver uptake (lSUVmax) were 
taken as internal references. 
Results interpretation 
Histological confirmation was taken as the gold standard when available. In the cohort 
without histological correlations, thrombus that resolved after anticoagulation therapy, was 
regarded as bland thrombus; whereas, progression of thrombus on follow-up imaging was 
regarded as indirect marker of tumor involvement.   
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Statistics 
Mean ± standard deviation, and range were used as descriptive statistical analysis. The 
mean SUVmax of mediastinal blood pool, liver background, tumor and bland thromboses 
were compared using Mann-Whitney U test for non-parametric data. Receiver operating 
characteristic curve (ROC curve) was produced to identify an optimal cut-off value of 
SUVmax to differentiate tumor thrombus from bland thrombus. All statistical analyses were 
performed using the statistical package SPSS for Windows (Version 11.0, SPSS, Chicago). A 
p-value of <0.05 was considered to indicate statistical significance. 
 
Results 
Patients 
Forty patients were identified to have VTE from our database; only 15 patients had 
histological confirmation and imaging follow-up to determine the nature of VTE. Therefore 
15 patients were included in the study analysis.  
There were 7 males and 8 females with mean age of 62.7 years (median 58.5 years, range 
46-76 years). All 15 patients had known primary malignancies and PET/CT scans were 
performed for staging/restaging or treatment evaluation. 5 patients had more than one site 
of VTE, giving rise to 24 sites of VTE for analysis. Demographic characteristics of the patients 
were tabulated in Table 1.  
None of the above patients had concurrent inflammatory conditions at the time of PET/CT, 
therefore minimising the possibility of thrombophlebitis or pylephlebitis, which can give rise 
to increased metabolic activity29, as cause of hypermetabolic thrombus. 
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Classification of thromboses 
There were 18 sites of tumor thromboses and 6 sites of bland thromboses.  
8 VTE sites had histological confirmation (Figure 2) while 16 sites had imaging follow-up in 
the form of PET/CT, MRI, contrast enhanced CT (Figure 3) and US Doppler studies. The mean 
follow-up period was 143±104 days (range 16-365 days).  
PET/CT 
Among the 18 sites of tumor thromboses, direct invasion from tumors or metastases was 
present in 5 sites and contiguous spread in 10 sites; while the remaining 3 sites were remote 
from the tumors or metastases. On contrast-enhanced CT, 7 sites (39%) demonstrated 
intra-thrombus neovascularity based on visual analysis and 9 sites (50%) had 
inhomogeneous intra-thrombus enhancement (Table 1). 
All 6 bland VTE sites (100%) were remote from tumors or metastases, and none showed 
neovascularity. 2 bland thromboses demonstrated intra-thrombus enhancement based on 
visual analysis. 
The mSUVmax and lSUVmax, as internal references, showed no statistical significance 
between tumor thrombosis and bland thrombosis (p=0.734and p=0.865 respectively).  
The differences between tSUVmax, and mSUVmax and lSUVmax were statistically significant 
(both p<0.001).  The mean SUVmax for bland thrombosis group was 1.5 ± 0.5 (range 
0.7-2.0) and the mean SUVmax for tumor thrombosis group was 4.5 ± 4.5 (range 1.0-14.8).  
The difference between bSUVmax and tSUVmax was statistically significant (p=0.005) 
(Figure 4). 
On ROC analysis, a cut-off SUVmax of 2.25 will yield 78% sensitivity and 100% specificity, in 
differentiating tumor thrombosis from bland thrombosis (Figure 5). 
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If this is corrected against the mediastinal blood pool uptake (tSUVmax /mSUVmax), ROC 
analysis showed that a cut-off ratio of 1.58 will produce sensitivity of 83% and specificity 
100% (Figure 6). 
If the three outliers within the tumor thrombosis group were excluded (SUVmax 13.3, 14.2 
and 14.8, see Figure 4), the ROC analysis produced similar results and the optimal cut-off 
SUVmax 2.25 remained unchanged (Figure 7). 
In the 2 bland thromboses that exhibited intra-thrombus enhancement, the metabolic 
uptake was less than SUVmax 2.25 (SUVmax 1.9 and SUVmax 2.0 respectively). Therefore, 
FDG PET using SUVmax cut-off of 2.25 changed the contrast-enhanced CT diagnosis in 33% 
of bland thromboses. 
 
Discussion 
Previously described CT features that help to differentiate tumor from bland thrombus14, 15 
include direct invasion from tumor and neovascularity within the thrombus; whereas 
generalized thrombus enhancement and contiguous spread can be helpful to increase 
diagnostic confidence.  Our results agreed with previous published data14. The lower 
incidence of intra-thrombus neovascularity found in our study could be explained by 
acquisition of CT images during the venous phase as neovascularity is easier to detect in 
early arterial phase of the contrast dynamic.  
Previous three retrospective series 26-28 using PET/ unenhanced CT have suggested that the 
metabolic uptake within the thrombus can be used to detect tumor thrombosis. Summary 
of these three studies were tabulated in Table 2. 
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The FDG avidities in the primary tumors varied in this cohort comprising of heterogeneous 
types of tumors. Previous study has demonstrated positive correlation between the level of 
uptake in the primary tumor and tumor thrombus 28. Therefore there is no surprise that the 
range of tSUVmax varied considerably. 
ROC analysis identified that a cut-off of SUVmax 2.25 can be employed to differentiate 
tumor from bland thrombosis with sensitivity of 78%, specificity 100% and accuracy 88%. 
Using this cut-off value, all the bland thromboses that had CT features of intra-thrombus 
enhancement could be excluded, thus increasing the specificity of PET/CT. 
Tumor thrombosis commonly develops from direct or contiguous spread from the primary 
tumor or metastasis. The process could involve intra-luminal extension of tumor without 
invasion of the vascular endothelium or direct invasion into the segment of venous 
circulation. The presence of endothelial invasion tends to preclude successful surgical 
thrombolectomy and the risk of tumor spread is higher. This may partly explain why the 
presence of tumor thrombosis has different prognostic impact on different carcinomas. For 
example hepatocellular carcinoma commonly invades the portal vein producing tumor 
thrombosis, and is associated with poorer outcome. In renal cell carcinoma, tumor 
thrombus can propagate into the renal vein and inferior vena cava without invasion of the 
vascular endothelium.  Therefore, if the tumor thrombus can be successfully resected, it 
will not be of any prognostic significance in patient’s survival30.  
In our study, contrast-enhanced CT was performed sequentially with FDG PET. Although 
there has been concern regarding the impact of IV contrast on CT-based attenuation 
correction, especially in regions of dense IV contrast 31; this study assessed regions of 
relatively lower IV contrast concentration in the venous circulation (performed at 70 
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seconds after IV contrast injection), and therefore is not expected to significantly affect the 
CT-based attenuation coefficient 32 .  
This study has several limitations. The study includes a heterogeneous group of tumors 
which have different FDG avidities and hence, the varied FDG uptake in the tumor thrombus.  
The lack of true gold standard in some of the cases may also introduce bias into the analysis 
of this study, as histological confirmation was only limited to 8 VTE sites. The sample 
number is small, although the results were of statistical significance despite the small 
numbers. We agree with previous authors 28 that larger study is required and ideally with 
histological validations of the diagnoses.  
 
Conclusion 
The measurement of SUVmax on FDG PET is of additional value to contrast-enhanced CT in 
differentiating tumor thrombosis from bland thrombosis, especially in excluding the 
presence of tumor thrombosis using SUVmax cut-off value of 2.25. This information will 
enhance the accuracy of scan interpretation especially with the increasing use of diagnostic 
contrast-enhanced CT together with FDG PET, as a ‘one-stop shop’. 
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Legends 
Table 1. Demographic details with sites of thromboses, presence of positive signs on 
contrast-enhanced CT suggestive of tumor thrombosis, metabolic uptake, categorization of 
types of thrombosis and confirmatory evidence. Pink rows: tumor thrombi; Light green rows: 
bland thrombi; Ca: carcinoma; PV: portal vein; IVC: inferior vena cava; LA: left atrium; SMV: 
superior mesenteric vein; IJV: internal jugular vein; SVC: superior vena cava; PE: pulmonary 
embolism; IMV: inferior mesenteric vein; ceCT: contrast-enhanced CT; D: direct invasion; C: 
contiguous spread; R: remote from tumor; N: neovascularity; E: intra-thrombus 
enhancement; mSUVmax: mediastinal SUVmax; lSUVmax: liver SUVmax; FU: follow-up 
Table 2. Summary of three retrospective studies describing the usefulness of FDG PET in 
detecting tumor thrombus and their relevant findings. 
Figure 1. 42 year-old female with ovarian carcinoma and left common iliac vein thrombosis. 
Coronal contrast-enhanced CT and coronal fused PET/CT with manually placed ROI over the 
site of bland thrombosis for SUVmax measurement. 
Figure 2a. 58 year-old lady with left renal cell carcinoma. Coronal fused PET/CT 
demonstrates hypermetabolic left RCC (red solid arrow) with hypermetabolic tumor 
thrombus (white solid arrow) extending into the left renal vein and IVC. On visual inspection, 
the tumor thrombus has higher metabolic activity compared to background liver and 
mediastinal blood pool.  
Figure 2b. 58 year-old lady with left renal cell carcinoma. Axial contrast enhanced CT 
demonstrates heterogeneous filling defect in the left renal vein, extending into the IVC 
(white solid arrow), which are distended, compatible with venous thromboses.  
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Figure 3a. 58 year-old man with primary rectal leiomyosarcoma. Maximum intensity 
projection demonstrates multiple hypermetabolic nodal, liver and osseous metastases. 
Figure 3b. 58 year-old man with primary rectal leiomyosarcoma. Fused coronal PET/CT 
demonstrates linear hypermetabolic left common femoral vein tumor thrombus (red solid 
arrow), SUVmax 3.4. 
Figure 3c. 58 year-old man with primary rectal leiomyosarcoma. Corresponding coronal 
contrast enhanced CT demonstrates filling defect in the left common femoral vein which is 
distended, consistent with venous thrombosis. 
Figure 4. Box-plot demonstrates the SUVmax of bland thrombosis group and tumor 
thrombosis group. The difference between the two groups are statistically significant, 
p=0.005 (Mann-Whitney U Test). 
Figure 5. ROC curve produces a cut-off value of SUVmax 2.25, with 78% sensitivity and 100% 
specificity (area under curve, AUC index 0.889) to differentiate tumor from bland 
thromboses. 
Figure 6. ROC curve produces a cut-off ratio tSUVmax/mSUVmax of 1.58, with 83% 
sensitivity and 100% specificity (AUC index 0.88) to differentiate tumor from bland 
thromboses. 
Figure 7. ROC curve excluding the three outliers, produces the same cut-off SUVmax of 2.25, 
with 83% sensitivity and 100% specificity (AUC index 0.876) to differentiate tumor from 
bland thromboses. 
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Figure 1 
 
Figure 2a.      Figure 2b. 
 
Figure 3a.      Figure 3b. 
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Figure 3c.      Figure 4. 
 
Figure 5.        Figure 6 
 
Figure 7.  
 
 
